tbuckley/cabot-search huggingface dataset:
<i>In Vivo</i> Imaging of Tumor Metabolism and Acidosis by Combining PET and MRI-CEST pH Imaging
Authors: Dario L. Longo, Antonietta Bartoli, Lorena Consolino, Paola Bardini, Francesca Arena, Markus Schwaiger, Silvio Aime
Journal: Cancer Research (2016)

Abstract The vast majority of cancers exhibit increased glucose uptake and glycolysis regardless of oxygen availability. This metabolic shift leads to an enhanced production of lactic acid that decreases extracellular pH (pHe), a hallmark of the tumor microenvironment. In this way, dysregulated tumor pHe and upregulated glucose metabolism are linked tightly and their relative assessment may be useful to gain understanding of the underlying biology. Here we investigated noninvasively the in vivo correlation between tumor 18F-FDG uptake and extracellular pH values in a murine model of HER2+ breast cancer. Tumor extracellular pH and perfusion were assessed by acquiring MRI-CEST (chemical exchange saturation transfer) images on a 3T scanner after intravenous administration of a pH-responsive contrast agent (iopamidol). Static PET images were recorded immediately after MRI acquisitions to quantify the extent of 18F-FDG uptake. We demonstrated the occurrence of tumor pHe changes that report on acidification of the interstitial fluid caused by an accelerated glycolysis. Combined PET and MRI-CEST images reported complementary spatial information of the altered glucose metabolism. Notably, a significant inverse correlation was found between extracellular tumor pH and 18F-FDG uptake, as a high 18F-FDG uptake corresponds to lower extracellular pH values. These results show how merging the information from 18F-FDG-uptake and extracellular pH measurements can improve characterization of the tumor microenvironment. Cancer Res; 76(22); 6463–70. ©2016 AACR.
Efficacy of Combination with Interferon and Nucleos(t) IDE Analogues as Simultaneous or Sequential Therapy in Patients with Chronic Hepatitis B
Authors: N. Jiang, J. Pan, X. Yang, J. Lin, R. Huang, S. Wang, X. Geng, R. Yang, T. Luo, J. Wu, K. Xu
Journal: Journal of Hepatology (2016)
Dementia strategy has not cut antipsychotic prescribing in care homes, study finds
Authors: Susan Mayor
Journal: BMJ (2016)

A national dementia strategy including recommendations to limit inappropriate use of antipsychotics has not reduced prescribing of these drugs in residential care homes in England, shows a study assessing the policy’s impact.1

The “off label” use of antipsychotics for behavioural and psychological symptoms in dementia has caused concern for some time. The national dementia strategy, launched in the United Kingdom in 2009, recommended that any prescribing of these drugs in people with dementia should …
C-Swift Retreatment Final Results: Highly Successful Retreatment of GT1-Infected Patients with 12 Weeks of Elbasvir/Grazoprevir plus Sofosbuvir and Ribavirin after Failure of Short-Duration All-Oral Therapy
Authors: E.J. Lawitz, F. Poordad, J. Gutierrez, J. Wells, C. Landaverde, J. Reiling, J.J. Li, H.-C. Huang, M. Robertson, J. Wahl, E. Barr, B. Haber
Journal: Journal of Hepatology (2016)
Hepatocellular Autophagy Deficiency in Mice Modulates the Unfolded Protein Response in a Pathway Selective Manner
Authors: W.J. Kwanten, Y.-P. Vandewynckel, W. Martinet, B.Y. De Winter, P.P. Michielsen, V. Van Hoof, A. Driessen, J.-P. Timmermans, P. Bedossa, H. Van Vlierberghe, S.M. Francque
Journal: Journal of Hepatology (2016)
High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin among Patients with Decompensated Cirrhosis who Underwent Liver Transplant during Participation in the Solar-1 and -2 Studies
Authors: B. Müllhaupt, P. Kwo, K. Agarwal, C. Duvoux, F. Durand, M. Peck-Radosavljevic, E.M. Yoshida, L. Lilly, B. Willems, H. Vargas, P. Kumar, R.S. Brown, Y. Horsmans, S. De-Oertel, S. Arterburn, H. Dvory-Sobol, D.M. Brainard, J.G. McHutchison, N. Terrault, M. Rizzetto
Journal: Journal of Hepatology (2016)
Functional capacity in heart failure: Comparison of methods for assessment and their relation to other indexes of heart failure
Authors: R. F. Smith, G. Johnson, S. Ziesche, Geetha Bhat, K. Blankenship, J. N. Cohn
Journal: Circulation (1993)

Background. Left ventricular (LV) dysfunction plays a primary role in the pathogenesis of congestive heart failure and correlates with prognosis, hut a strong quantitative relation between exercise performance and indexes of LV function has not been demonstrated. We examined the relation between LV ejection fraction at rest, oxygen consumption at peak exercise (VO 2 ), patient and physician assessments of clinical severity, and other clinical attributes in 804 patients with moderate heart failure. Methods and Results. Ejection fraction correlated weakly with VO 2 , and mean ejection fraction was related to severity of symptoms
Implications of Gene and p53 Protein Alterations in Determining Progression of Chronic Myeloid Leukemia Phases.
Authors: Geraldo Barroso Cavalcanti, Eliane Pereira, Marcos Antônio Mauricio Sheiner, Flavia da Cunha Vasconcelos, Claudete Esteves Klumb, Raquel Ciuvalschi Maia
Journal: Blood (2004)
Determination of Stage Specific Markers for Liver Fibrosis in Hepatitis B: A Comparative Tissue Proteomic Study
Authors: S. Katrinli, K. Ozdil, A. Sahin, O. Ozturk, G. Kir, A.T. Baykal, O.S. Sarac, M. Sokmen, G.D. Doganay, H.L. Doğanay
Journal: Journal of Hepatology (2016)
Inflammatory breast carcinoma signature and relapse-free survival in patients with noninflammatory breast cancer
Authors: S. J. Van Laere, G. G. Van den Eynden, I. Van der Auwera, X. B. Trinh, P. A. van Dam, E. A. Van Marck, P. B. Vermeulen, L. Y. Dirix
Journal: Journal of Clinical Oncology (2008)

11048 Background: Inflammatory Breast Carcinoma (IBC) is an aggressive form of breast cancer associated with poor patient survival. We hypothesize that a gene expression profile characteristic for IBC might be related to tumour aggressiveness in nIBC. Methods: RNA from 19 IBC samples and 40 nIBC samples was hybridized onto Affymetrix chips. A gene signature predictive of IBC was identified and applied onto 7 publicly available gene expression data sets (1157 nIBC samples) with survival data of 881 nIBC samples (4 data sets). Samples were classified as “IBC-like” or “nIBC-like”. Relapse Free Survival (RFS) was compared between these groups by the Kaplan-Meyer method. We classified the 1157 nIBC breast cancer samples according to other prognostically relevant gene signatures and compared these classifications with the IBC signature classification. Cox regression analysis was performed to identify the most predictive signature with respect to RFS. Results: Patients with an “IBC-like” phenotype demonstrate a shorter RFS interval in all 4 data sets (p=0.049, p=0.032, p<0.0001, p=0.0005). Classification according to the IBC signature is significantly (p<0.0001) associated with the cell-of-origin subtypes-, the Wound Healing Response (WHR)-, the Invasive Gene Signature-, the Genomic Grade Index (GGI)- and the Fibroblastic Neoplasm Signature. Significant associations (p<0.0001) were found between the IBC signature and tumour grade and ER status. Cox regression analysis on the entire data set of 881 nIBC samples identified the IBC signature as an independent predictor of RFS (RR=1.532, C.I.=1.100–2.133, p=0.012), together with the WHR and GGI. Conclusions: We demonstrate that nIBC breast tumours having an “IBC-like” phenotype have a reduced RFS interval. This suggests that IBC and nIBC tumours demonstrate the same phenotypic traits with respect to aggressive tumour cell behaviour. Gene signatures related to tumour stroma and tumour grade add information regarding patient survival. Hence the IBC signature represents a different aspect of aggressive tumour behaviour. No significant financial relationships to disclose.
Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)
Authors: Mark B Pepys, Louise M Cookson, Sharon V Barton, Alienor C Berges, Thirusha Lane, David Hutt, Marianna Fontana, James C Moon, Julian D Gillmore, Ashutosh Wechalekar, Philip N Hawkins, Duncan B Richards
Journal: Blood (2015)
Effect of specific targeting of a modified salmonella typhymurium on cancer metastases.
Authors: K. Hayashi, M. Zhao, H. Tsuchiya, S. Miwa, K. Tomita, R. M. Hoffman
Journal: Journal of Clinical Oncology (2010)

e13649 Background: Cancer metastasis is the life-threatening aspect of cancer and is usually resistant to standard treatment. We report here a tumor targeting and cure strategy for cancer metastasis using a modified auxotrophic strain of Salmonella(S.)typhimurium. Methods: The genetically modified strain of S. typhimurium is auxotrophic for the amino acids arginine and leucine. These mutations preclude growth in normal tissue but do not reduce bacterial virulence in tumor cells. The tumor-targeting strain of S. typhimurium, termed A1-R and expressing green fluorescent protein (GFP), was administered to both axillary lymph and popliteal lymph node metastasis of human pancreatic cancer and fibrosarcoma, respectively, as well as lung metastasis of the fibrosarcoma in nude mice. Results: The bacteria were delivered via a lymphatic channel to target the lymph-node metastases and systemically via the tail vein to target the lung metastasis. The cancer cells expressed red fluorescent protein (RFP) in the cytoplasm and GFP in the nucleus linked to histone H2B, enabling color-coded real-time imaging of the bacteria targeting the metastatic tumors. After 7-21 days of treatment, the metastases were cured without the need of chemotherapy or any other treatment. No adverse effects were observed. Conclusions: This new strategy demonstrates the clinical potential of targeting and curing cancer metastasis with engineered bacteria without the need of toxic chemotherapy. No significant financial relationships to disclose.
Histopathologic Features of Descemet Membrane Endothelial Keratoplasty Graft Remnants, Folds, and Detachments
Authors: Thomas M. Müller, Robert M. Verdijk, Itay Lavy, Marieke Bruinsma, Jack Parker, Perry S. Binder, Gerrit R.J. Melles
Journal: Ophthalmology (2016)
Realworld Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Experienced Cirrhotic Genotype 1 Patients with Chronic Hepatitis C: A Comparative Analysis of Gilead Sponsored Trials with 4 Real-World Cohorts
Authors: M. Curry, A.A. Modi, S. Pungpapong, M. Leise, B. Aqel, J. Llewellyn, L.A. Williams, M. Natha, D.M. Brainard, B. Kreter, A. Kholi, D. Wyles, Y. Lee, R. Reddy
Journal: Journal of Hepatology (2016)
Preclinical Evaluation of A Potent 2nd Generation Small-Molecule Hsp90 Inhibitor STA-9090 In Hematological Cell Lines
Authors: Weiwen Ying, David Proia, Suqin He, Jim Sang, Kevin Foley, Zhenjian Du, Ronald k Blackman, Yumiko Wada, Lijun Sun, Keizo Koya
Journal: Blood (2010)
A retrospective comparative outcome analysis following systemic therapy in <scp>M</scp>ycosis fungoides and <scp>S</scp>ezary syndrome
Authors: Walter Hanel, Robert Briski, Charles W. Ross, Thomas F. Anderson, Mark S. Kaminski, Alexandra C. Hristov, Ryan A Wilcox
Journal: American Journal of Hematology (2016)

Cutaneous T‐cell lymphomas (CTCL), with few exceptions, remain incurable and treatment is largely palliative. We performed a retrospective analysis of systemic treatment outcomes of patients diagnosed with MF/SS. We identified 223 patients with MF/SS evaluated at a single institution from 1997 to 2013. Disease stage at diagnosis, time of treatment, and treatments received were retrospectively analyzed using our CTCL database. The primary endpoint was time to next treatment (TTNT). Treatment outcomes were analyzed using Kaplan–Meier method and comparisons among groups were made using log‐rank analysis. A superior TTNT was associated with retinoid or interferon therapies when compared with HDAC inhibitors or systemic chemotherapy. Retinoids and interferon were associated with superior TTNT in both limited‐stage and advanced stage disease. Extracorporeal photophoresis (ECP) had a superior TTNT in Sezary Syndrome. HDAC inhibitors and chemotherapy were associated with inferior TTNT in both limited stage disease and advanced stage disease. With the exception of interferon, retinoids, or ECP, durable responses are rarely achieved with systemic therapies in MF/SS patients, particularly those with advanced‐stage disease. Therefore, clinical trial participation with novel agents should be encouraged. Am. J. Hematol. 91:E491–E495, 2016. © 2016 Wiley Periodicals, Inc.
Nomogram for 5-year relapse-free survival of a patient with advanced gastric cancer after surgery
Authors: Yusuke Muneoka, Kohei Akazawa, Takashi Ishikawa, Hiroshi Ichikawa, Atsushi Nashimoto, Hiroshi Yabusaki, Norio Tanaka, Shin-ichi Kosugi, Toshifumi Wakai
Journal: International Journal of Surgery (2016)
Non-invasive and quantitative analysis for EGFR T790M mutation in the patients with advanced non-small cell lung cancer received EGFR-TKI therapy.
Authors: Rui Chen, Tongtong An, Jie Wang, Hua Bai, Zhijie Wang, Jun Zhao, Meina Wu, Minglei Zhuo, Jianchun Duan, Yuyan Wang, Shuhang Wang
Journal: Journal of Clinical Oncology (2013)

e19101 Background: Approximately 50% of advanced non-small cell lung cancer (A-NSCLC) patients with EGFR sensitive mutation who develop acquired resistance to EGFR-TKIs reportedly have a secondary EGFR T790M mutation. Establishing a dynamical, quantitative and noninvasive detection system of EGFR T790M mutation in process of disease therapy for NSCLC is critical to personalized targeted therapy. Methods: 135 A-NSCLC patients with EGFR mutation who received EGFR-TKIs and presented acquired resistance (PFS≥6 months) were included into this study. All patients provided the plasma samples for molecular analysis when disease progressed. 109 patients of them had matched TKI-naive plasma. T790M mutation was measured qualitatively and quantitatively by ARMS and Digital PCR (DggPCR), respectively. Association of T790M mutation with clinical charateristics were evaluated. Results: DgPCR was more sensitive than ARMs to detect T790M mutation in plasma [pre-treatment 29.4% (32/109) VS 5.5% (6/109); post-treatment: 43.0% (58/135) VS 25.2% (34/135)]. 32 patients with pre-treatment T790M mutation predicted shorter PFS and OS compared with 77 T790 M negative patients (PFS, F 12.7 VS 9.2 months, P=0.004, GOS, F 27.0 VS 18.8 months, P=0.002). Patients with or without post-treatment T790M mutation have no significantly different PFS and OS. However, quantified the ratio of copy number of mutant T790M to wild-type by DgPCR, patients were divided into high-frequency groups (≥5%), low-frequency group (0%-5%) and wild-group (0%) according to the number of positive signals observed from DgPCR results. 12 patients in high-frequency group showed shorter PFS and OS compared with wild group and low-frequency group (PFS 9.5 VS 11.9 months, P=0.033, G9.5 VS 13.6 months, P=0.028, GOS, F 18.5 VS 21.2 months, P=0.044, 18.5 VS 28.8 months, P=0.001). Conclusions: Non-invisive and quantitative detection of T790m mutation by digital PCR is feasible in clinical practice. High contents of T790M when disease progression after EGFR-TKIs therapy predicted poor prognosis.
PHOTOAFFINITY-LABELING WITH 8-AZIDO[ALPHA-32P] ATP OF THE ATP-DEPENDENT GLUTATHIONE CONJUGATE TRANSPORTER IN CANALICULAR PLASMA-MEMBRANES FROM NORMAL WISTAR AND GY MUTANT RATS
Authors: P Zimniak, S Ziller, A Radominska, Mieke Blaauw, Hendrik Wolters, Folkert Kuipers, M Saxena, S Singhal, Roelf Vonk, Y Awasthi, R Lester
Journal: Hepatology (1991)
Impressive Gains in Patient-Reported Outcomes are Observed in Chronic Hepatitis C Patients with or without Cirrhosis who are Treated with Sofosbuvir and Velpatasvir: Results from Astral-1, -2, -3 and-4
Authors: Z.M. Younossi, M. Stepanova, J. Feld, S. Zeuzem, M. Sulkowski, G.R. Foster, A. Mangia, M. Charlton, J.G. O’Leary, M.P. Curry, S. Hunt
Journal: Journal of Hepatology (2016)
Incidence of HCV Reinfection among Treated Individuals with Recently Acquired Infection
Authors: M. Martinello, K. Petoumenos, J. Grebely, Ed Gane, M. Hellard, D. Shaw, J. Sasdeusz, T. Applegate, F. Lamoury, B. Yeung, L. Maire, G. Dore, G. Matthews
Journal: Journal of Hepatology (2016)
Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC<sub>120</sub> in the adjuvant treatment of breast cancer patients: The German ADEBAR study.
Authors: W. Janni, N. Harbeck, H. L. Sommer, B. K. Rack, D. Augustin, W. Simon, A. Wischnik, K. Anneke, K. Friese, M. Kiechle
Journal: Journal of Clinical Oncology (2010)

535 Background: Based on meta-analytic evidence, taxane containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. However, in the MA-21 study, AC-P was significantly inferior to FEC120. We prospectively compared a sequential epirubicin-docetaxel chemotherapy regimen to FEC120. Methods: The ADEBAR study was a multicenter phase III trial (n=1502) to evaluate whether breast cancer (BC) pts with > 3 axillary lymph node metastases benefit from a sequential anthracycline-docetaxel regimen (E90C–D: 4 cycles epirubicin [E] 90 mg/m2 plus cyclophosphamide [C] 600 mg/m2 q21 days followed by 4 cycles docetaxel [D] 100 mg/m2 q21 days) compared to dose-intensive anthracycline-containing chemotherapy (FE120C: 6 cycles E 60 mg/m2; d 1+8, 5-FU 500 mg/m2; d 1+8 and C 75 mg/m2; d 1-14, q4 weeks). The median follow-up time was 47 mts.(range 2-83 mts). Results: Treatment was stopped prematurely in 3.7% of the pts in the E90C–D arm and in 8.0% in the FE120C arm due to toxicity (p = 0.0009). Antibiotic treatment was given in 10.4% (E90C–D) vs. 19.7% (FE120C), G-CSF support in 39.2% vs 61.4 % and erythropoietin stimulation in 8.7% vs. 20.0%, respectively (p < 0.0001). Haematological toxicity was significantly higher in the FE120C-arm. 128 events of recurrence were observed in the FE120C group and 153 in the E90C–D group. The hazard ratio (HR) was 0.88 (95 percent confidence interval, 0.694 to 1.115; p = 0.2197, log-rank test). Overall survival in the two groups was not significantly different: HR 0.99, 0.73-1.35, p = 0.99. Subgroup analyses, stratifying for tumor size, lymph node involvement, hormone receptor and HER2-neu status showed no significant difference between the two treatment arms and will be presented in detail. Conclusions: Different toxicity profiles given, hematological toxicity in the FE120C group was more severe than in the E90C–D. In contrast to AC-P in earlier studies, EC-Doc provides a feasible and effective alternative option to dose-intensified FEC with different saftey profile in this high risk breast cancer cohort. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, AstraZeneca, sanofi-aventis AstraZeneca, sanofi-aventis
Prognosis Value of Skeletal Muscle Index and Alpha Fetoprotein Score in Patients Treated by Trans-Arterial Chemoembolization
Authors: E. Soum, C. Teilhet, G. Lamblin, L. Muti, L. Poincloux, L. Boyer, P. Chabrot, B. Pereira, A. Abergel
Journal: Journal of Hepatology (2016)
Dicer Prevents Hypoxia-Induced Up-Regulation of HIF-1A, Hypoxic Response and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Authors: A.A. Ibrahim, C. Schmithals, E. Kowarz, V. Köberle, B. Kakoschky, T. Pleli, O. Waidmann, F. Finkelmeier, S. Zeuzem, H.W. Korf, B. Kronenberger, R. Marschalek, A. Piiper
Journal: Journal of Hepatology (2016)
Alternate chemopreventive mechanisms of action of resveratrol and muscadine grape skin extract in prostate cancer
Authors: Tamaro S. Hudson, Nomeli Nunez, Stephen Hurstings, Susan Perkins, Diane Hartle, Jeffrey Green
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

2263 

Human prostate cancer is one of the most insidious diseases among men in the Western hemisphere, with few long-term medial treatment options. Identifying methods of preventing clinically significant prostate cancer would, therefore, provide a major advance in public health. Accordingly, there is intense effort to identify naturally-occurring or synthetic agents that may have chemopreventive activity against prostate cancer. Phytochemicals are a class of agents that have been shown to be effective against many different types of cancers. Within this class of agents is resveratrol, a phytoalexin found in grapes, nuts, and wildberries which has been shown to have inhibitory effects against prostate cancer, possibly through anti-oxidant activities. In contrast, muscadine grape seed extract, which also contains phytochemicals, has been shown to inhibit prostate cancer by inducing apoptosis. Despite the biological importance of these phytochemicals, no studies have yet compared the biological potency or mechanisms of action between theses compounds against prostate cancer progression. Human prostate transformed cell lines (RWPE-1, WPE1-NA22, WPE1-NB14, WPE1-NB26) are an excellent model of prostate cancer progression which we have used to compare the biological efficacy of these agents during the multi-step process of prostate carcinogenesis. Therefore, our purpose is to investigate the preventive effects of resveratrol and muscadine grape skin extract (GSE) on prostate tumor progression using a set of human cell lines that mimic prostate progression. We demonstrate that while both agents appear to inhibit prostate tumor cell growth, the mechanisms of action are strikingly different. Our data show that at twenty four hours the compounds induce significant changes in the morphology of all four cell lines that differ between resveratrol and GSE. In addition, propidium iodide and annexin V-FITC FACS analysis indicates that at 24 hours resveratrol arrest the cells in the G1 phase of the cell cycle, whereas GSE induces apoptosis. Furthermore, in situ cell death fluorescence analysis by TUNEL (Terminal deoxynucleotidyl transferase (TDT)) confirms that GSE induces apoptosis in all four cell lines. Consistent with these results is the observation that resveratrol induces overexpression of p21 protein, an inhibitor of cell cycle regulator cyclin E. Thus, these results demonstrate that resveratrol and GSE act on very different pathways to inhibit prostate cancer cell growth. Ongoing studies will further determine whether similar mechanisms are active in vivo , further suggesting that resveratrol and muscadine grape extract may be viable preventive or therapeutic agents against prostate tumor development.
Can We Continue after Liver Transplantation with HCV Treatment Started on List? (Hepa-C Registry Case Series)
Authors: C. Fernández-Carrillo, G. Crespo, J. de la Revilla, L. Castells, M. Buti, J.L. Montero, J. Crespo, I. Fernández, C. Serrano-Millán, V. Hernández, M.C. Londoño
Journal: Journal of Hepatology (2016)
Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia
Authors: Guido Finazzi, Alessandra Carobbio, Paola Guglielmelli, Elisa Rumi, Silvia Salmoiraghi, Alessandro M. Vannucchi, Mario Cazzola, Francesco Passamonti, Alessandro Rambaldi, Tiziano Barbui
Journal: Blood (2014)
Cost Effectiveness of Covered Transjugular Intrahepatic Portosystemic Shunt versus Endoscopic Treatment for Secondary Prevention of Gastro-Oesophageal Variceal Bleeding
Authors: J. Harki, I. Lisanne Holster, S. Polinder, A. Moelker, H.R. van Buuren, E.J. Kuipers, E.T.T.L. Tjwa
Journal: Journal of Hepatology (2016)
Hepatic Encephalopathy is an Independent Risk Factor for Transplant-Free Survival in Patients Awaiting Liver Transplantation
Authors: A.J. Kerbert, E. Reverter, L. Verbruggen, M. Tieleman, M. Navasa, M. de Vree, H.J. Metselaar, F.W. Chiang, H.W. Verspaget, B. van Hoek, J. Bosch, M.J. Coenraad
Journal: Journal of Hepatology (2016)
Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting, 2005–2014: The Hits-P Study
Authors: E.B. Cunningham, F. Luciani, B. Hajarizadeh, B. Betz-Stablein, N.A. Bretana, S. Teutsch, G.J. Dore, J. Grebely, A.R. Lloyd
Journal: Journal of Hepatology (2016)